WO2001089622A1 - Applicator having abrading surface coated with substance to be applied to skin - Google Patents
Applicator having abrading surface coated with substance to be applied to skin Download PDFInfo
- Publication number
- WO2001089622A1 WO2001089622A1 PCT/US2001/016121 US0116121W WO0189622A1 WO 2001089622 A1 WO2001089622 A1 WO 2001089622A1 US 0116121 W US0116121 W US 0116121W WO 0189622 A1 WO0189622 A1 WO 0189622A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- substance
- delivery
- abrading
- abrasion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
Definitions
- This invention relates to topical delivery of substances into the skin, particularly by disruption of the stratum corneum and delivery of the substance to the epidermal layer beneath.
- the epidermis itself is a particularly desirable target for drug delivery as it is rich in antigen presenting cells, h comparison, the dermis contains fewer antigen presenting cells.
- the stratum corneum and epidermis do not contain nerves or blood vessels, so this method has the advantage of being essentially painless and blood-free while giving access to the skin layers capable of responding to the antigen.
- the prior art reports a variety of devices and methods for disrupting the stratum corneum for the purpose of delivering substances to the body. For example, breach of the stratum corneum may be achieved by puncturing as taught in US Patent 5,679,647 to Carson, et al.
- narrow diameter tynes such as those found on devices used for tuberculin skin tests and allergy tests, can be coated with polynucleotides and used for delivery of such materials into the skin.
- the method of using such devices involves puncturing the skin with the tynes resulting in intracutaneous injection of the coated substance. This is in contrast to the present invention, where it has been unexpectedly discovered that substances coated onto the surface of narrow diameter micro-protrusions are delivered more effectively by lateral abrasion across the skin surface rather than by puncturing.
- the present invention provides optimized methods for topical delivery of substances, particularly nucleic acids, amino acids, amino acid derivatives, peptides or polypeptides. It has been discovered that nucleic acids exhibit enhanced gene expression and produce an enhanced immune response to the expressed protein when they are delivered simultaneously with abrasion of the stratum corneum. Similarly, allergens delivered simultaneously with abrasion produce a more vigorous immune response than conventional allergen testing methods.
- Fig. 1 illustrates levels of gene expression obtained with the various nucleic acid delivery protocols tested in Example 1.
- Fig. 2 illustrates levels of gene expression obtained by varying the number of abrasions as described in Example 2.
- Fig. 3 illustrates levels of gene expression obtained by varying the formulation of the nucleic acid and the delivery protocol as described in Example 3.
- Fig. 4 illustrates the antibody response following topical delivery of plasmid DNA as described in Example 4. DETAILED DESCRIPTION OF THE INVENTION
- abrasion refers to disruption of the outer layers of the skin, for example by scraping or rubbing, resulting in an area of disrupted stratum corneum. This is in contrast to "puncturing" which produces discrete holes through the stratum corneum with areas of undisrupted stratum corneum between the holes.
- substances such as nucleic acid-based vaccines and peptides or polypeptides are applied to the skin simultaneously with abrasion rather than being applied to previously abraded skin. That is, the substance is abraded into the skin rather than being passively applied to skin which has been previously abraded. This method results in improved delivery and response as compared to post-abrasion application.
- the substance may be delivered into the skin in any pharmaceutically acceptable form, but a liquid or gel formulation is preferred.
- the substance is applied to the skin and an abrading device is then moved or rubbed reciprocally over the skin and the substance. It is preferred that the minimum amount of abrasion to produce the desired result be used. Determination of the appropriate amount of abrasion for a selected substance is within the ordinary skill in the art.
- the substance may be applied in dry form to the abrading surface of the delivery device prior to application, h this embodiment, a reconstituting liquid is applied to the skin at the delivery site and the substance-coated abrading device is applied to the skin at the site of the reconstituting liquid.
- nucleic acid preparations may also be coated on the abrading device in the form of a gel, although the improvement in gene expression is not as significant as in certain other embodiments of the invention.
- any device known in the art for disruption of the stratum corneum by abrasion can be used in the methods of the invention. These include, for example, microelectromechanical (MEMS) devices with arrays of short microneedles or microprotrusions, sandpaper-like devices, scrapers and the like.
- MEMS microelectromechanical
- the abrading device does not include a reservoir for containment and discharge of fluids from the device, the substance-containing liquid or the reconstituting liquid must be separately applied to the skin prior to abrading, for example from a separate dispenser or pump.
- reservoirs may be an integral part of the abrading device.
- the reservoir is in fluid communication with the abrading surface of the device, for example via channels through the needles or protrusions, or via channels which exit the reservoir between such needles or protrusions, or via porous materials.
- the substance or reconstituting liquid is contained in the reservoir of the abrading device and is dispensed to the skin surface prior to abrasion or simultaneously with abrasion.
- the abrading device may also include means for controlling the rate of delivery of the substance or reconstituting liquid, or for controlling the amount of substance or reconstituting liquid delivered.
- Nucleic acids for use in the methods of the invention may be RNA or DNA. They may be in any physical form suitable for topical administration and for uptake and expression by cells.
- nucleic acid may be formulated in a pharmaceutically acceptable formulation such as a fluid or gel which is compatible with the nucleic acid.
- Pharmaceutically acceptable peptide and polypeptide formulations for use in the invention, including formulations for allergen compositions, are also well known in the art.
- nucleic acid delivery it has been found that minimal abrasion (as little as one pass over the skin) is sufficient to produce an improvement in nucleic acid delivery to skin cells.
- the amount of nucleic acid delivery and expression continues to increase with increasing numbers of abrasive passes over the skin. Six abrasive passes or more gave the maximum improvement in nucleic acid delivery in our experimental systems. Although all abrasive passes over the skin may be in the same direction, it is preferred that the direction be altered during abrasion.
- the most commonly used protocol for delivery of nucleic acid vaccines today is IM injection, usually with additional response enhancers when the dose is low. Determination of the appropriate dose of nucleic acid vaccine to be delivered using the methods of the invention is within the ordinary skill in the art.
- nucleic acid vaccines is more efficient than LM delivery even without response enhancers, as evidenced by levels of gene expression and stimulation of an immune response.
- Amino acids, amino acid derivatives, peptides and polypeptides, particularly allergens may also be delivered topically according to the methods of the invention. Allergens are conventionally delivered into the skin by intracutaneous puncture using devices similar to the tuberculin tyne test. However, it has been unexpectedly found that an enhanced allergenic response can be obtained by simultaneous abrasion and delivery. This produces a more sensitive test and has the advantage that a minor or imperceptible response to the conventional allergen test may be more easily detected using the methods of the invention.
- Plasmid DNA (35 ⁇ g) encoding firefly licuferase was administered to anesthetized BALB/c mice by IM injection or ID injection with a standard 30 g needle and 1 cc syringe, or was administered topically using a 200 ⁇ m silicon microneedle array. Two protocols were used for DNA administration using the microneedle array:
- ABRdel Simultaneous abrasion and delivery
- Pre-abrasion After shaving as described above, a 1 cm 2 site was pre- abraded by lateral movement of the microarray across the skin surface six times with alternating direction (three passes in each of two directions). The DNA solution was then spread over the abraded skin surface and left to air dry as above.
- DNA solution was applied topically to the 1 cm shaved skin site and left to air dry.
- RLU Relative Light Units
- Luciferase plasmid DNA 35 ⁇ g was administered by ABRdel as described in Example 1, but the number of lateral passes of the device across the skin surface was varied (12, 10, 6, 4 and 2 times).
- the microneedle array was repetitively pressed against the skin (six times) to simulate puncture-mediated delivery.
- Topical application of the DNA solution in the absence of abrasion (noABR) was included as a control for possible DNA delivery through hair follicles or nicks.
- Skin biopsies (1 cm 2 ) were collected 24 hr. after application and were assayed for luciferase activity as described in Example 1.
- Increasing levels of gene expression were attained with increasing numbers of passes of the microneedle array across the skin surface.
- Mean levels of expression ranged from greater than 1,000- to 2,800- fold above noABR controls in groups treated by six or more abrasions.
- Mean responses following 4, 2, or 1 pass of the device across the surface of the skin were about 300-, 200- and
- Luciferase plasmid (35 ⁇ g) was administered as a liquid formulation by ID injection or by simultaneous abrasion and delivery ("ABRdel liquid”) with six passes of the microneedle device across the skin surface as described in Example 1.
- the DNA was lyophilized to a powder and coated onto the surface of the microneedle array and administered by simultaneous abrasion and delivery either directly as a powder (“ABRdel powder”) or upon reconstitution in PBS buffer at the time of application (ABRdel powder/recon”). Reconstitution was accomplished by placing the powder-coated array in direct contact with a droplet of PBS on the surface of the skin, followed by simultaneous abrasion and delivery.
- Microneedle arrays were also coated with DNA dissolved in 0.5% agarose gel and administered by simultaneous abrasion and delivery as described above ("ABRdel gel"). Topical application of the liquid formulation in the absence of abrasion (noABR) was included as a control. Skin biopsies (1 cm 2 ) were collected 24 hr. after application and were assayed as described in Example 1.
- Plasmid DNA encoding the Hepatitis B surface antigen (HbsAg) was administered to anaesthetized BALB/c mice by IM or ID injection with a standard 30 g needle and 1 cc syringe, or was administered topically using a 200 ⁇ m silicon solid microneedle array according to the ABRdel protocol of Example 1. Mice were given a total of three immunizations of 100 ⁇ g per dose. Serum samples were analyzed by ELISA for antibodies to HbsAg (total Ig) 2-3 weeks following each immunzation. DNA was applied topically to shaven but anabraded (noABR) skin as control for possible delivery through nicks or hair follicles. Data represent an anti-HbsAg titer, defined as the highest dilution of a serum sample yielding absorbance values at least three times above background (serum obtained from naive, unimmunized mice).
- mice per group were analyzed. Mean titers are represented as bars in Figure 4, with the responses of individual mice indicated as open symbols. The results indicate that the ABRdel protocol induces strong serum antibody responses in vivo. The magnitude of such responses were significantly greater p ⁇ 0.05 after immunizations 2 and 3) than those induced via either IM (the current standard for DNA-based vaccine delivery) and ID injections. In addition, the responses following ABRdel were considerably less variable than those observed following either standard needle-based injection route. Mean titers after three immunizations were 12,160 for the ABRdel group, compared to 820 following IM injection and 4800 via ID injection.
- the ABRdel approach was the most effective delivery route following two immunizations; 100% (10/10) of animals treated via ABRdel seroconverted after two immunizations, compared to 40% (4/10) via the LM route and 50% (5/10) via ID injection. None of the animals administered plasmid DNA topically in the absence of abrasion mounted a detectable antibody response. Further characterization of the antibody isotypes revealed that ABRdel induces a similar mixed response as standard needle- based IM and ID injections, consisting of both IgGl and IgG2a.
- Histamine dihydrochloride (2.5 mg) was administered to the skin of anaesthetized swine by simultaneous abrasion and delivery using a 200 ⁇ m silicon solid microneedle array, as described in Example 1 (ABRdel; 4 passes of the device across the skin surface).
- the histamine was formulated either as a liquid or as a lyopholized powder which was coated onto the surface of the microarray and reconstituted in water directly on the skin at the time of application.
- histamine solution was placed as a droplet onto the surface of the skin, immediately after which a tyne-like device was placed in contact with this solution and used to puncture the skin.
- This tyne-like device consisted of seven metal 34 g needles of 1 mm length, similar to commercially available devices used in allergen testing. Adjacent skin sites were treated with the microarray or the tyne-like puncturing device in the absence of histamine in order to monitor skin reactions due to the devices rather than the effects of histamine. Additional controls included skin sites treated with histamine topically in the absence of abrasion or puncture. Skin sites were monitored for immediate inflammatory reactions including redness, swelling and the appearance of a wheal-and-flare.
- Vigorous inflammatory reactions were observed at skin sites treated with histamine via the solid microneedle array. Severe erythema and swelling (up to 2 mm of raised tissue) were observed across the entire area of histamine treated skin, whereas sites treated with the device in the absence of histamine displayed only mild redness along the path of abrason in the complete absence of swelling. Similarly intense reactions were observed with both liquid and reconstituted powder histamine formulations. Skin sites treated with the histamine solution using the tyne-like puncturing device also displayed severe erythema and swelling, although the response was localized to the points of contact of the tynes and the immediate surrounding area. Skin sites treated topically with histamine solution in the absence of abrasion or puncture were not inflammed and appeared indistinguishable from normal, untreated skin.
- Histamine dihydrochloride is used in the art as a model system for evaluation of peptide and polypeptide allergens. These results indicate that the described protocol of simultaneous abrasion and delivery can be effectively used for the topical administration of allergens which are amino acids or amino acid derivatives, and predict similar results for delivery of peptide or polypeptide allergens. Benefits of allergen delivery by microabrasion compared to skin puncture include distribution of the substance to a wider surface area of the skin, thus increasing the reactogenic site compared to the localized distribution accomplished using puncture with tyne-like devices.
- the increased area of distribution, combined with better targeting of the highly immune-stimulatory epidermal tissue may increase the sensitivity of allergen testing compared to current tyne-based skin puncture testing methods.
- delivery according to the current invention is likely to be less invasive and safer than current testing methods.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU6175701A AU6175701A (en) | 2000-05-22 | 2001-05-18 | Applicator having abrading surface coated with substance to be applied to skin |
AU2001261757A AU2001261757B2 (en) | 2000-05-22 | 2001-05-18 | Applicator having abrading surface coated with substance to be applied to skin |
AT01935686T ATE272423T1 (en) | 2000-05-22 | 2001-05-18 | APPLICATOR WITH SUBSTANCE COATED ON AN ABRASIVE SURFACE FOR APPLICATION TO SKIN |
JP2001585860A JP4801309B2 (en) | 2000-05-22 | 2001-05-18 | Applicator with an abrasion surface coated with a substance to be applied to the skin |
MXPA02011557A MXPA02011557A (en) | 2000-05-22 | 2001-05-18 | Applicator having abrading surface coated with substance to be applied to skin. |
CA002410561A CA2410561C (en) | 2000-05-22 | 2001-05-18 | Applicator having abrading surface coated with substance to be applied to skin |
BRPI0111345-3A BR0111345B1 (en) | 2000-05-22 | 2001-05-18 | applicator device having a substance coated abrasive surface to be applied to the skin. |
DE60104686T DE60104686T2 (en) | 2000-05-22 | 2001-05-18 | APPLICATOR WITH SUBSTANCE COVERED ON A SLICING SURFACE FOR APPLYING TO SKIN |
EP01935686A EP1289599B1 (en) | 2000-05-22 | 2001-05-18 | Applicator having abrading surface coated with substance to be applied to skin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/576,643 US6595947B1 (en) | 2000-05-22 | 2000-05-22 | Topical delivery of vaccines |
US09/576,643 | 2000-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001089622A1 true WO2001089622A1 (en) | 2001-11-29 |
Family
ID=24305324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/016121 WO2001089622A1 (en) | 2000-05-22 | 2001-05-18 | Applicator having abrading surface coated with substance to be applied to skin |
Country Status (12)
Country | Link |
---|---|
US (3) | US6595947B1 (en) |
EP (1) | EP1289599B1 (en) |
JP (1) | JP4801309B2 (en) |
CN (1) | CN100394995C (en) |
AT (1) | ATE272423T1 (en) |
AU (2) | AU2001261757B2 (en) |
BR (1) | BR0111345B1 (en) |
CA (1) | CA2410561C (en) |
DE (1) | DE60104686T2 (en) |
ES (1) | ES2222376T3 (en) |
MX (1) | MXPA02011557A (en) |
WO (1) | WO2001089622A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2828648A1 (en) * | 2001-08-16 | 2003-02-21 | Adam Bouaziz | CONSTITUTION OF AN EXTRACTIBLE VACCINE FROM AN IMMUNOGENIC INSERT. |
EP1482893A1 (en) * | 2002-02-14 | 2004-12-08 | Mattioli Engineering Limited | Method and apparatus for skin absorption enhancement and cellulite reduction |
WO2005067968A1 (en) * | 2003-10-02 | 2005-07-28 | Becton, Dickinson And Company | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
EP1592443A1 (en) * | 2003-02-13 | 2005-11-09 | Becton, Dickinson and Company | Improved anthrax vaccines and delivery methods |
WO2011135309A1 (en) | 2010-04-29 | 2011-11-03 | University College Cork | Vaccination method using microneedle arrays |
DE102017126501A1 (en) | 2017-11-10 | 2019-05-16 | Lts Lohmann Therapie-Systeme Ag | Micro needle system for the application of a hepatitis vaccine |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9302903B2 (en) * | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
ATE471990T1 (en) * | 2001-08-13 | 2010-07-15 | Univ Rochester | TRANSCUTANE IMMUNIZATION AGAINST PAPILLOMAVIRUS WITH VIRUS-LIKE PAPILLOMAVIRUS PARTICLES |
US6908453B2 (en) * | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
CN1691969A (en) | 2002-07-19 | 2005-11-02 | 3M创新有限公司 | Microneedle devices and microneedle delivery apparatus |
TW200409657A (en) * | 2002-08-08 | 2004-06-16 | Alza Corp | Transdermal vaccine delivery device having coated microprotrusions |
JP2005537057A (en) * | 2002-08-29 | 2005-12-08 | ベクトン・ディキンソン・アンド・カンパニー | Microprojection array and method for delivering substance into tissue using the same |
AU2003278798A1 (en) * | 2002-09-12 | 2004-04-30 | Children's Hospital Medical Center | Method and device for painless injection of medication |
AU2004268616B2 (en) * | 2003-08-25 | 2010-10-07 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US20050095283A1 (en) * | 2003-09-16 | 2005-05-05 | Aphios Corporation | Compositions and methods for topically treating diseases |
EP1680178A4 (en) * | 2003-10-31 | 2008-01-02 | Alza Corp | System and method for transdermal vaccine delivery |
CA2552385C (en) * | 2003-12-29 | 2013-07-23 | 3M Innovative Properties Company | Medical devices and kits including same |
WO2005079440A2 (en) * | 2004-02-17 | 2005-09-01 | Children's Hospital Medical Center | Improved injection devicew for administering a vaccine |
EP1718452A1 (en) * | 2004-02-23 | 2006-11-08 | 3M Innovative Properties Company | Method of molding for microneedle arrays |
US20050220854A1 (en) * | 2004-04-01 | 2005-10-06 | Yuh-Fun Maa | Apparatus and method for transdermal delivery of influenza vaccine |
US20050271684A1 (en) * | 2004-04-13 | 2005-12-08 | Trautman Joseph C | Apparatus and method for transdermal delivery of multiple vaccines |
ES2650188T3 (en) * | 2004-06-10 | 2018-01-17 | 3M Innovative Properties Company | Device and patch application kit |
EP1768742A4 (en) * | 2004-07-06 | 2007-10-17 | Transpharma Medical Ltd | Delivery system for transdermal immunization |
US7316665B2 (en) * | 2004-08-25 | 2008-01-08 | Becton, Dickinson And Company | Method and device for the delivery of a substance including a covering |
AU2005306422A1 (en) | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Low-profile microneedle array applicator |
AU2005306426B2 (en) * | 2004-11-18 | 2011-04-28 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
CN101060882B (en) | 2004-11-18 | 2010-06-16 | 3M创新有限公司 | Microneedle array applicator and retainer |
EP1827715B1 (en) | 2004-11-18 | 2013-07-17 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
JP2008522875A (en) | 2004-12-07 | 2008-07-03 | スリーエム イノベイティブ プロパティズ カンパニー | Microneedle molding method |
JP5301985B2 (en) | 2005-04-07 | 2013-09-25 | スリーエム イノベイティブ プロパティズ カンパニー | System and method for tool feedback sensing |
US20080009802A1 (en) * | 2005-04-25 | 2008-01-10 | Danilo Lambino | Method of treating acne with stratum corneum piercing device |
US20070270738A1 (en) * | 2005-04-25 | 2007-11-22 | Wu Jeffrey M | Method of treating ACNE with stratum corneum piercing patch |
US20060253078A1 (en) * | 2005-04-25 | 2006-11-09 | Wu Jeffrey M | Method of treating skin disorders with stratum corneum piercing device |
WO2007002523A2 (en) | 2005-06-24 | 2007-01-04 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
EP1901799B1 (en) * | 2005-06-27 | 2012-06-13 | 3M Innovative Properties Company | Microneedle array applicator device |
EP1896115B2 (en) | 2005-06-27 | 2020-01-22 | 3M Innovative Properties Company | Microneedle cartridge assembly |
US20070009542A1 (en) * | 2005-07-05 | 2007-01-11 | Galit Levin | Method and device for transdermal immunization |
EP2258441A3 (en) | 2005-09-02 | 2011-09-21 | Intercell USA, Inc. | Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs |
US20080262416A1 (en) * | 2005-11-18 | 2008-10-23 | Duan Daniel C | Microneedle Arrays and Methods of Preparing Same |
CA2629193C (en) * | 2005-11-18 | 2016-03-29 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
WO2007075614A1 (en) * | 2005-12-21 | 2007-07-05 | 3M Innovative Properties Company | Microneedle devices |
US9610459B2 (en) | 2009-07-24 | 2017-04-04 | Emkinetics, Inc. | Cooling systems and methods for conductive coils |
US9339641B2 (en) | 2006-01-17 | 2016-05-17 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US9119945B2 (en) * | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
US9005102B2 (en) | 2006-10-02 | 2015-04-14 | Emkinetics, Inc. | Method and apparatus for electrical stimulation therapy |
JP2010505471A (en) | 2006-10-02 | 2010-02-25 | エムキネティクス, インコーポレイテッド | Method and apparatus for magnetic induction therapy |
US10786669B2 (en) | 2006-10-02 | 2020-09-29 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US11224742B2 (en) | 2006-10-02 | 2022-01-18 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US20090054333A1 (en) * | 2006-10-17 | 2009-02-26 | Antonio Giordano | Peptide inhibitors of cyclin-dependent kinase activity and uses thereof |
US20080214987A1 (en) * | 2006-12-22 | 2008-09-04 | Nanomed Devices, Inc. | Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances |
US8795197B2 (en) * | 2007-07-17 | 2014-08-05 | Histologics, LLC | Frictional trans-epithelial tissue disruption collection apparatus and method of inducing an immune response |
EP2166965B1 (en) | 2007-07-17 | 2017-05-17 | Neal Marc Lonky | Frictional trans-epithelial tissue disruption and collection apparatus |
CA2704740C (en) * | 2007-10-09 | 2016-05-17 | Transpharma Ltd. | Magnetic patch coupling |
WO2009072108A2 (en) | 2007-12-05 | 2009-06-11 | Syneron Medical Ltd. | A disposable electromagnetic energy applicator and method of using it |
DE202009017814U1 (en) | 2008-01-17 | 2010-07-01 | Syneron Medical Ltd. | Hair removal device for personal use |
KR20100115748A (en) | 2008-01-24 | 2010-10-28 | 시네론 메디컬 리미티드 | A device, apparatus, and method of adipose tissue treatment |
US8778003B2 (en) | 2008-09-21 | 2014-07-15 | Syneron Medical Ltd | Method and apparatus for personal skin treatment |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
US8606366B2 (en) | 2009-02-18 | 2013-12-10 | Syneron Medical Ltd. | Skin treatment apparatus for personal use and method for using same |
US8834423B2 (en) | 2009-10-23 | 2014-09-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
AU2010313487A1 (en) | 2009-10-26 | 2012-05-24 | Emkinetics, Inc. | Method and apparatus for electromagnetic stimulation of nerve, muscle, and body tissues |
US9044213B1 (en) | 2010-03-26 | 2015-06-02 | Histologics, LLC | Frictional tissue sampling and collection method and device |
US8588884B2 (en) | 2010-05-28 | 2013-11-19 | Emkinetics, Inc. | Microneedle electrode |
JP2015515886A (en) | 2012-05-01 | 2015-06-04 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Tip-loaded microneedle array for percutaneous insertion |
US10201332B1 (en) | 2012-12-03 | 2019-02-12 | Healoe Llc | Device and method of orienting a biopsy device on epithelial tissue |
US20140297784A1 (en) * | 2013-03-29 | 2014-10-02 | Lucy Ma Zhao | Cross Platform Application Transactions |
BR112016017736A2 (en) * | 2014-01-31 | 2017-10-10 | Factor Bioscience Inc | Methods and Products for Nucleic Acid Production and Distribution |
JP7199809B2 (en) | 2015-02-13 | 2023-01-06 | ファクター バイオサイエンス インコーポレイテッド | Nucleic acid product and its administration method |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
WO2017066768A1 (en) | 2015-10-16 | 2017-04-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices |
WO2017120322A1 (en) | 2016-01-05 | 2017-07-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
US11013466B2 (en) | 2016-01-28 | 2021-05-25 | Healoe, Llc | Device and method to control and manipulate a catheter |
IL308824A (en) | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of administration thereof |
WO2018178976A1 (en) | 2017-03-27 | 2018-10-04 | Novoxel Ltd. | System, device and method for intradermal solution delivery |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
GB2125280A (en) * | 1982-08-18 | 1984-03-07 | Hyman Goldberg | Surgical scrubbing device |
US4483348A (en) * | 1982-03-25 | 1984-11-20 | Nathan Sher | Skin testing device |
US5003987A (en) | 1987-09-11 | 1991-04-02 | Grinwald Paul M | Method and apparatus for enhanced drug permeation of skin |
DE19518974A1 (en) * | 1994-05-23 | 1995-11-30 | Samsung Electro Mech | Perforator for dispensing pharmaceutical product through skin |
WO1996007369A1 (en) * | 1994-09-05 | 1996-03-14 | Cyanamid Websters Pty. Limited | Scratch vaccine applicator and/or method of applying a vaccine |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5879326A (en) | 1995-05-22 | 1999-03-09 | Godshall; Ned Allen | Method and apparatus for disruption of the epidermis |
US5983136A (en) * | 1996-09-17 | 1999-11-09 | Deka Products Limited Partnership | System for delivery of drugs by transport |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3289670A (en) * | 1964-03-09 | 1966-12-06 | Milo Bundy Corp | Device for abrading and applying biologicals to the skin of a patient |
US3351059A (en) * | 1964-06-02 | 1967-11-07 | Norman Lettvin | Single stable dose vaccinator |
US3556080A (en) * | 1968-04-08 | 1971-01-19 | Lincoln Lab Inc | Skin allergy testing device |
US4270548A (en) * | 1979-09-05 | 1981-06-02 | Aller-Screen, Inc. | Allergy testing method |
US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
CA2008262A1 (en) * | 1989-01-30 | 1990-07-30 | John A. Gilly | Clinical applicator |
EP0429842B1 (en) * | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
SU1724181A1 (en) | 1990-03-22 | 1992-04-07 | Ивано-Франковский Государственный Медицинский Институт | Tester for chamber-scarification skin testing |
TW279133B (en) * | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
DE4117900A1 (en) | 1991-05-31 | 1992-12-03 | Spantec Werkzeugtechnik Gmbh | ROLL MILLING |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5273528A (en) * | 1992-07-10 | 1993-12-28 | Skeen Mikell L | Livestock inoculator |
DE4307869C2 (en) * | 1993-03-12 | 1996-04-04 | Microparts Gmbh | Microstructure body and process for its manufacture |
US5885211A (en) * | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5380337A (en) * | 1994-01-24 | 1995-01-10 | Romaine; Richard A. | Mesh-type skin biopsy appliance |
US5660680A (en) * | 1994-03-07 | 1997-08-26 | The Regents Of The University Of California | Method for fabrication of high vertical aspect ratio thin film structures |
DE19518932C2 (en) * | 1994-05-23 | 1999-03-18 | Samsung Electro Mech | Device for perforating the skin for the preparation of a transdermal medication |
US5591139A (en) * | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
WO1996037256A1 (en) * | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical patch for enhancing the delivery of compounds through the skin |
JPH0910307A (en) * | 1995-06-30 | 1997-01-14 | Pentel Kk | Injection syringe holder |
US5958589A (en) | 1995-07-07 | 1999-09-28 | The United States Of America As Represented By The Secretary Of Agriculture | Starch-based microcellular foams |
DE19525607A1 (en) | 1995-07-14 | 1997-01-16 | Boehringer Ingelheim Kg | Transcorneal drug delivery system |
US5658515A (en) * | 1995-09-25 | 1997-08-19 | Lee; Abraham P. | Polymer micromold and fabrication process |
GB9520209D0 (en) | 1995-09-25 | 1995-12-06 | Cawley R | Skin cleaning apparatus |
US6032060A (en) * | 1996-01-25 | 2000-02-29 | 3M Innovative Properties Company | Method for conditioning skin and an electrode by passing electrical energy |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
ATE234129T1 (en) | 1996-06-18 | 2003-03-15 | Alza Corp | DEVICE FOR IMPROVING TRANSDERMAL ADMINISTRATION OF MEDICATIONS OR EXTRACTION OF BODY FLUID |
US5919364A (en) * | 1996-06-24 | 1999-07-06 | Regents Of The University Of California | Microfabricated filter and shell constructed with a permeable membrane |
ES2200187T3 (en) | 1996-07-03 | 2004-03-01 | Altea Therapeutics Corporation | MULTIPLE MECHANICAL MICROPORATION OF THE SKIN OR MUCOSA. |
US5910306A (en) * | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
AU6036998A (en) | 1997-01-24 | 1998-08-18 | Regents Of The University Of California, The | Apparatus and method for planar laminar mixing |
US5928207A (en) * | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
US5931794A (en) | 1997-10-21 | 1999-08-03 | Pitesky; Isadore | Allergy testing apparatus |
IL122016A (en) * | 1997-10-22 | 2001-09-13 | Tav Tech Ltd | Apparatus for dermal abrasion |
CA2313458C (en) * | 1997-12-11 | 2007-04-17 | Alza Corporation | Device for enhancing transdermal agent flux |
CA2321596C (en) | 1998-02-25 | 2012-05-29 | Gregory M. Glenn | Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin |
US5970998A (en) | 1998-02-27 | 1999-10-26 | The Regents Of The University Of California | Microfabricated cantilever ratchet valve, and method for using same |
US6173202B1 (en) | 1998-03-06 | 2001-01-09 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
US6106751A (en) | 1998-03-18 | 2000-08-22 | The Regents Of The University Of California | Method for fabricating needles via conformal deposition in two-piece molds |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
US6835184B1 (en) * | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
US6331266B1 (en) * | 1999-09-29 | 2001-12-18 | Becton Dickinson And Company | Process of making a molded device |
US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
JP4312407B2 (en) * | 1999-12-10 | 2009-08-12 | アルザ・コーポレーション | Skin treatment device for sustained transdermal drug delivery |
-
2000
- 2000-05-22 US US09/576,643 patent/US6595947B1/en not_active Expired - Lifetime
-
2001
- 2001-05-18 BR BRPI0111345-3A patent/BR0111345B1/en not_active IP Right Cessation
- 2001-05-18 ES ES01935686T patent/ES2222376T3/en not_active Expired - Lifetime
- 2001-05-18 AT AT01935686T patent/ATE272423T1/en not_active IP Right Cessation
- 2001-05-18 AU AU2001261757A patent/AU2001261757B2/en not_active Ceased
- 2001-05-18 CN CNB018099157A patent/CN100394995C/en not_active Expired - Fee Related
- 2001-05-18 AU AU6175701A patent/AU6175701A/en active Pending
- 2001-05-18 EP EP01935686A patent/EP1289599B1/en not_active Expired - Lifetime
- 2001-05-18 WO PCT/US2001/016121 patent/WO2001089622A1/en active IP Right Grant
- 2001-05-18 MX MXPA02011557A patent/MXPA02011557A/en active IP Right Grant
- 2001-05-18 CA CA002410561A patent/CA2410561C/en not_active Expired - Lifetime
- 2001-05-18 JP JP2001585860A patent/JP4801309B2/en not_active Expired - Fee Related
- 2001-05-18 DE DE60104686T patent/DE60104686T2/en not_active Expired - Lifetime
-
2003
- 2003-05-13 US US10/436,757 patent/US20030191085A1/en not_active Abandoned
-
2007
- 2007-09-07 US US11/851,956 patent/US7731968B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4483348A (en) * | 1982-03-25 | 1984-11-20 | Nathan Sher | Skin testing device |
GB2125280A (en) * | 1982-08-18 | 1984-03-07 | Hyman Goldberg | Surgical scrubbing device |
US5003987A (en) | 1987-09-11 | 1991-04-02 | Grinwald Paul M | Method and apparatus for enhanced drug permeation of skin |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
DE19518974A1 (en) * | 1994-05-23 | 1995-11-30 | Samsung Electro Mech | Perforator for dispensing pharmaceutical product through skin |
WO1996007369A1 (en) * | 1994-09-05 | 1996-03-14 | Cyanamid Websters Pty. Limited | Scratch vaccine applicator and/or method of applying a vaccine |
US5879326A (en) | 1995-05-22 | 1999-03-09 | Godshall; Ned Allen | Method and apparatus for disruption of the epidermis |
US5983136A (en) * | 1996-09-17 | 1999-11-09 | Deka Products Limited Partnership | System for delivery of drugs by transport |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2828648A1 (en) * | 2001-08-16 | 2003-02-21 | Adam Bouaziz | CONSTITUTION OF AN EXTRACTIBLE VACCINE FROM AN IMMUNOGENIC INSERT. |
WO2003015743A1 (en) * | 2001-08-16 | 2003-02-27 | Adam Bouaziz | Immunisation by means of the local implantation of antigens which are irreversibly fixed to a bioadherent |
EP1482893A1 (en) * | 2002-02-14 | 2004-12-08 | Mattioli Engineering Limited | Method and apparatus for skin absorption enhancement and cellulite reduction |
EP1592443A1 (en) * | 2003-02-13 | 2005-11-09 | Becton, Dickinson and Company | Improved anthrax vaccines and delivery methods |
EP1592443A4 (en) * | 2003-02-13 | 2007-02-21 | Becton Dickinson Co | Improved anthrax vaccines and delivery methods |
WO2005067968A1 (en) * | 2003-10-02 | 2005-07-28 | Becton, Dickinson And Company | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
WO2011135309A1 (en) | 2010-04-29 | 2011-11-03 | University College Cork | Vaccination method using microneedle arrays |
DE102017126501A1 (en) | 2017-11-10 | 2019-05-16 | Lts Lohmann Therapie-Systeme Ag | Micro needle system for the application of a hepatitis vaccine |
WO2019092257A1 (en) | 2017-11-10 | 2019-05-16 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for applying a hepatitis vaccine |
Also Published As
Publication number | Publication date |
---|---|
AU6175701A (en) | 2001-12-03 |
CA2410561A1 (en) | 2001-11-29 |
US6595947B1 (en) | 2003-07-22 |
ES2222376T3 (en) | 2005-02-01 |
JP4801309B2 (en) | 2011-10-26 |
AU2001261757B2 (en) | 2004-04-01 |
CN100394995C (en) | 2008-06-18 |
US7731968B2 (en) | 2010-06-08 |
BR0111345A (en) | 2004-02-03 |
DE60104686D1 (en) | 2004-09-09 |
BR0111345B1 (en) | 2010-10-05 |
MXPA02011557A (en) | 2004-09-06 |
US20030191085A1 (en) | 2003-10-09 |
EP1289599A1 (en) | 2003-03-12 |
ATE272423T1 (en) | 2004-08-15 |
DE60104686T2 (en) | 2005-08-11 |
US20080009785A1 (en) | 2008-01-10 |
JP2003534065A (en) | 2003-11-18 |
CN1430526A (en) | 2003-07-16 |
CA2410561C (en) | 2009-05-12 |
EP1289599B1 (en) | 2004-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6595947B1 (en) | Topical delivery of vaccines | |
AU2001261757A1 (en) | Applicator having abrading surface coated with substance to be applied to skin | |
EP1439870B1 (en) | Device for the delivery of a substance | |
JP4917540B2 (en) | Method and apparatus for supplying a substance containing a coating | |
EP1086718B1 (en) | Apparatus for the transdermal administration of a substance | |
US20020198509A1 (en) | Intradermal delivery of vaccines and gene therapeutic agents via microcannula | |
US7963935B2 (en) | Microprojection array having a beneficial agent containing coating | |
Grice et al. | Electrical and physical methods of skin penetration enhancement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001261757 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2410561 Country of ref document: CA Ref document number: 018099157 Country of ref document: CN Ref document number: IN/PCT/2002/01674/MU Country of ref document: IN Ref document number: PA/A/2002/011557 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001935686 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001935686 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001261757 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001935686 Country of ref document: EP |